Significance of Testing Anti-HBcIgM Antibodies for the Screening of Hepatitis B in the Donor Blood.

BACKGROUND: The purpose to perform this study was to screen blood donors for possible occult HBV by checking the seroprevalence of the hepatitis B antibodies in blood donors. It was a Cross-sectional study conducted at Blood Bank of Lahore General Hospital Lahore from April to June 2015 (3-months). METHODS: In this prospective study, 180 healthy blood donors, presenting to the blood bank of Lahore General Hospital were selected. Their detailed demographic data and blood samples were collected. HBsAg testing was done by ELISA and further HBc IgM testing was also done by ELISA. Those testing positive for HBc IgM were further evaluated by real-time PCR to detect HBV DNA. RESULTS: Mean duration of the life span was 26.51 years with a range of 18-61 years. Sex distribution show 93.9% (n=169) males and 6.1% (n=11) females. HBsAg was positive in 3.3% (n=6) while their HBc IgM was negative and HBc IGM was positive in 2.2% (n=4) of the healthy donors in whom HBsAg was found negative by ICT method. further qualitative HBV DNA by rt-PCR was done on those positive with anti HBc IgM and no patient had HBV DNA detected from their blood. CONCLUSION: Without routine screening of the sera for the HBc Antibody, the low-level HBV viraemia may not be detected as the nonappearance of the surface antigen in the blood of apparently healthy donors do not ensure the absence of circulating virus in the blood of these donors.

Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients.

MicroRNAs (miRNAs) are small, non-coding RNAs that regulate a variety of biological processes. Recently, human liver-specific miRNA miR-122 has been reported to facilitate hepatitis C virus (HCV) replication in liver cells. HCV is one of the leading causes of liver diseases worldwide. In Pakistan, the estimated prevalence is up to 10%. Here, we report hepatic and serum miR-122 expression profiling from paired liver and serum samples from treatment-naive chronic hepatitis C (CHC) patients and controls. We aimed to elucidate the biomarker potential of serum miR-122 for monitoring disease progression and predicting end treatment response (ETR). Hepatic miR-122 levels were significantly down-regulated in CHC patients. A significant inverse correlation was observed between hepatic and serum miR-122 levels, indicating that serum miR-122 levels reflect HCV-associated disease progression. Both hepatic and serum miR-122 were significantly correlated (P < 0.05) with several clinicopathological features of CHC. Receiver operator curve analysis showed that serum miR-122 had superior discriminatory ability even in patients with normal alanine transaminase levels. Multivariate logistic regression analysis highlighted pre-treatment serum miR-122 levels as independent predictors of ETR. In conclusion, serum miR-122 holds the potential to serve as a promising biomarker of disease progression and ETR in CHC patients.